Kobayashi Pharmaceutical Co., Ltd.
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
kbypf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Kobayashi Pharmaceutical Co., Ltd. (KBYPF) measures how much investors pay for each dollar of the company's trailing earnings. KBYPF's current PE ratio of 133.36x is calculated by dividing its stock price of $34.05 by its TTM earnings per share of $41.27. +169.9% elevated vs 5Y avg 49.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%42.1x
MedianQ3 · 75%110.3x
Max
At 133.36x, KBYPF's current P/E is higher than in 100% of its annual fiscal year readings over the past 20 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Household & Personal Products · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Kobayashi Pharmaceutical Co., Ltd.You KBYPF | $2.5B | 133.36x | +342.2% | $41.27 |
 Société BIC S.A. BICEF | $2.8B | 24.51x | -18.7% | $2.09 |
 Blue Moon Group Holdings Limited BLUMY | $2.2B | N/A | — | -$0.31 |
 KWS SAAT SE & Co. KGaA KNKZF | $2.7B | 13.04x | -56.8% | $4.24 |
 KOSÉ Corporation KSRYY | $1.9B | 19.12x | -36.6% | $55.54 |
 Lion Corporation LIOPF | $3.2B | 16.50x | -45.3% | $99.83 |
 Milbon Co., Ltd. MIOFF | $1.7B | 77.64x | +157.4% | $106.26 |
Industry Average 5 peers with valid PE | — | 30.16x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 110.32x | $49.22 | +153.7% | |
2024-12-31 FY2024 | 43.48x | $135.42 | +49.6% | |
2023-12-31 FY2023 | 29.06x | $268.16 | +4.1% | |
2022-12-31 FY2022 | 27.92x | $259.61 | -23.2% | |
2021-12-31 FY2021 | 36.35x | $252.35 | +33.1% | |
2020-12-31 FY2020 | 27.31x | $245.70 | -5.6% | |
2019-12-31 FY2019 | 28.93x | $244.07 | +36.9% | |
2018-12-31 FY2018 | 21.13x | $228.04 | -14.0% | |
2017-12-31 FY2017 | 24.57x | $201.31 | -12.7% | |
2016-12-31 FY2016 | 28.15x | $191.13 | +17.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Kobayashi Pharmaceutical Co., Ltd. (KBYPF) measures how much investors pay for each dollar of the company's trailing earnings. KBYPF's current PE ratio of 133.36x is calculated by dividing its stock price of $34.05 by its TTM earnings per share of $41.27.
Frequently asked questions
KBYPF pe ratio · 6 questionsKBYPF's current PE ratio is 133.36x as of 2026-06-09, based on a stock price of $34.05 and TTM EPS of $41.27. Data sourced from Financial Modeling Prep via KBYPF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Kobayashi Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09